Fruquintinib Combined With Trastuzumab and XELOX as First-line Treatment in Patients With HER2-positive Advanced Gastric Cancer

Trial Details

NCT ID

NCT07334431

Phase

PHASE1 / PHASE2

Sponsor

Henan Cancer Hospital

Status

RECRUITING

Cancer Type

Gastric Cancer

Interventions

• fruquintinib＋trastuzumab + XELOX

Locations (sample)

• Zhengzhou, Henan, China|34.75778,113.64861

Key Eligibility Criteria

• Have fully understood the study and voluntarily signed the informed consent;
• 18-75 years old (including 18 and 75 years old);
• Pathologically determined advanced gastric or gastroesophageal junction adenocarcinoma;
• No previous anti-tumor treatment for metastatic diseases;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.